ライフサイエンスコーパス: verapamil

1 ipine, felodipine, nifedipine, diltiazem, or verapamil).

2 or no effect (haloperidol, moxifloxacin, and verapamil).

3 d PET scan of 60-min duration with (R)-(11)C-verapamil.

4 with the P-glycoprotein substrate (R)-[(11)C]verapamil.

5 Q-sensitive) P. falciparum by agents such as verapamil.

6 and in vivo in diabetic mice receiving oral verapamil.

7 oline, bradykinin, sodium nitroprusside, and verapamil.

8 more effective intracellularly than neutral verapamil.

9 poprotein (HDL) to the drugs propranolol and verapamil.

10 bited by the human ABCB1 and ABCC1 modulator verapamil.

11 rectional (45)Ca(2+) entry by nifedipine and verapamil.

12 fibrosis can be attenuated by treatment with verapamil.

13 Finally, we treated mice with verapamil.

14 Gating currents were unaffected by verapamil.

15 ling by pharmaceutically targeting Cx43 with verapamil.

16 t shows the SP phenotype and is sensitive to verapamil.

17 he absence and 180 microM in the presence of verapamil.

18 an be reversed by the channel-blocking agent verapamil.

19 the absence of transport substrates such as verapamil.

20 ent mice with the calcium channel antagonist verapamil.

21 ents, before and after infusion of 0.1 mg/kg verapamil.

22 lism reactions of amodiaquine, buspirone and verapamil.

23 bited by the chloroquine resistance-reverser verapamil.

24 c pigments but no such effects were seen for verapamil.

25 a low-dose therapy regimen of Cilengtide and Verapamil.

26 accumulation of the P-glycoprotein substrate verapamil.

27 IP shRNA-transfected mice or those receiving verapamil.

28 nts still symptomatic after beta-blockade or verapamil.

29 investigated the effect of carbamazepine and verapamil (0.005-10 mg/kg) on a range of plant responses

30 Verapamil (0.3 mg/kg) also inhibited TdP, but caused a 1

31 to induce hHcys, and TXNIP was inhibited by verapamil (1 mg/ml in drinking water) or by local microb

32 A combination of NS5806 (3-10 mumol/L) and verapamil (1 mumol/L) was used to pharmacologically mode

33 Propranolol (1.0 micromol/L) or verapamil (1.0 micromol/L) completely suppressed ectopic

34 odium nitroprusside (2 to 8 microg/min), and verapamil (10 to 100 microg/min) infusions 2 and 6 hours

35 S5806 (5 muM) and the Ca(2+)-channel blocker verapamil (2 muM) were used to pharmacologically mimic t

36 72 mg; diltiazem: 212 mg versus 180 mg, and verapamil: 276 mg versus 200 mg, respectively (p < 0.01

37 fter the intravenous administration of (11)C-verapamil (30-72 MBq/kg) before and during intravenous i

38 urred between 6 AM and noon in both the COER verapamil (99/277) and atenolol or hydrochlorothiazide (

39 ostasis, and these effects were mitigated by verapamil, a Ca(2+) channel blocker.

40 ions has been demonstrated by a synthesis of verapamil, a clinically used drug for the treatment of h

41 cancer cells, a 2-fold increase compared to verapamil, a first-generation chemosensitizer.

42 as having higher potency than compound 1 and verapamil, a first-generation P-gp modulator.

43 cin-resistant 4T1-R breast cancer cells with verapamil, a general inhibitor of P-glycoprotein, increa

44 blocking torsadogen used for intractable AF, verapamil, a non-torsadogenic MICE comparator and beprid

45 significantly reduced brain accumulation of verapamil, a P-glycoprotein substrate.

46 likely MDR-mediated because cotreatment with verapamil, a P-gp inhibitor, partially reversed the sele

47 studied the dynamic biodistribution of (11)C-verapamil, a P-gp substrate, in the nonhuman primate Mac

48 -coupled NorM transporters in complexes with verapamil, a small-molecule pharmaceutical that inhibits

49 In the presence of verapamil, a substrate that activates ATP hydrolysis, th

50 We found that standard TB chemotherapy plus verapamil accelerates bacterial clearance in C3HeB/FeJ m

51 We propose that verapamil achieves its inhibitory effect via occlusion o

52 ease verapamil, we evaluated the activity of verapamil added to standard chemotherapy in both C3HeB/F

53 ation (isoproterenol) and antagonist trials (verapamil) addressed ionotropic and chronotropic cell li

54 ese data demonstrate treatment shortening by verapamil adjunctive therapy in mice, and strongly suppo

55 Neither complementary fatty acid loading nor verapamil administered 1 h before (18)F-FDG injection co

56 in perfusion metrics between pre- and post- verapamil administrations.

57 ptor blockade, adenosine, nitroprusside, and verapamil against the aspirate-induced constriction were

58 Surprisingly, verapamil alone (1-300 microM) does not significantly af

59 Verapamil also gave similar behavior, with a K(a) of 6.0

60 Verapamil also improved transduction in human SCID (seve

61 Indomethacin and verapamil also inhibit the luminal Ca(2+) increase.

62 Verapamil also promoted beta-cell survival and improved

63 gonize these fluxes, including glyburide and verapamil, also inhibit inflammasome activation by cardi

64 phate receptor-mediated calcium release, and verapamil, an inhibitor of L-type calcium channels, pref

65 on with or without intracochlear infusion of verapamil, an L-type voltage-gated calcium channel antag

66 e voltage-gated Ca2+ channel (VGCC) blockers verapamil and (+)-cis-diltiazem significantly reduced th

67 progesterone and the efflux pump inhibitors verapamil and 1-(1-naphthylmethyl)-piperazine is consist

68 Here, we show that low doses of verapamil and 2-deoxyglucose, to accentuate the cost of

69 y, 8241 participants received 180 mg of COER verapamil and 8361 received either 50 mg of atenolol or

70 changes were suppressed by pretreatment with verapamil and amlodipine.

71 Flecainide, verapamil and atenolol significantly reduced power outpu

72 goxin, dobutamine, isoprenaline, flecainide, verapamil and atenolol.

73 ates calcein-AM, CellTrace RedOrange, BoDipy-verapamil and BoDipy-vinblastine, than any other cell in

74 (11)C-verapamil and compartmental analysis can estimate P-gp a

75 0-fold decrease in the apparent affinity for verapamil and cyclic peptide inhibitor QZ59-SSS was obse

76 progesterone), slightly overcoming those of verapamil and cyclosporin A.

77 of 40 patients met inclusion criteria, with verapamil and diltiazem accounting for 27 of 40 (67.5%)

78 3A-activated protein C (APC), intra-arterial verapamil and intra-arterial hypothermia were also asses

79 The content of verapamil and its metabolites in plasma samples was dete

80 of local infusions of the L-VGCC antagonists verapamil and nifedipine on both within-session extincti

81 al nitroglycerin ointment, and intraarterial verapamil and nitroglycerin.

82 onse of the heartbeat of zebrafish larvae to verapamil and norepinephrine, which are known to affect

83 isease to reproduce the effects of the drugs verapamil and octreotide, and we show that the experimen

84 mice, and strongly support further study of verapamil and other efflux pump inhibitors in human TB.

85 At the CP, verapamil and probenecid (but not indomethacin) signific

86 molecules or indirectly alter contractility (verapamil and propranolol).

87 with a detection limit of 8 and 25 fmol for verapamil and reserpine, respectively, and quantitation

88 macokinetic/pharmacodynamic relationships of verapamil and rifampin coadministration in mice.

89 Also, verapamil and TMB-8 were able to block the calcium respo

90 P-gp modulators verapamil and trans-flupenthixol and MDR1-targeted siRNA

91 n (by a factor of ~13, reaching 600 amol for verapamil), and extended dynamic range (6 orders of magn

92 th a labeled P-glycoprotein substrate, (11)C-verapamil, and (15)O-water to measure rCBF.

93 nated with adenosine, 2 of 2 terminated with verapamil, and 2 of 2 terminated with Valsalva.

94 Terfenadine, verapamil, and pinacidil each induced all-or-none repola

95 Norverapamil, R-verapamil, and potentially other derivatives present att

96 d type II cations (e.g., quinidine, quinine, verapamil, and rhodamine123) are also PMAT inhibitors.

97 nitroimidazole antifungal agents, diltiazem, verapamil, and troleandomycin; each doubles, at least, t

98 rted similar inhibition on calcium kinetics, verapamil applied the strongest inhibition on cardiomyoc

99 -generation calcium channel blockers such as verapamil are a widely used class of antihypertensive dr

100 Nitroprusside and verapamil are more potent than adenosine to attenuate th

101 TCC) blockers, represented by amlodipine and verapamil, are widely used antihypertensive drugs that a

102 rvative human bioequivalent doses, we tested verapamil as an adjunctive drug together with standard T

103 We used (11)C-verapamil as the prototypic P-gp substrate and cyclospor

104 the fraction of current blocked by 30 microM verapamil at 0.05 Hz stimulation.

105 ocking activity yet were similarly active as verapamil at inhibiting macrophage-induced drug toleranc

106 tagonistic drugs, nifedipine, diltiazem, and verapamil, at resolutions of 2.9 angstrom, 3.0 angstrom,

107 CCBs-nifedipine, amlodipine, diltiazem, and verapamil-at their physiological serum concentrations fo

108 orrespondingly, TXNIP shRNA transfection and verapamil attenuated hHcys-induced proteinuria, albuminu

109 tely 172 d) underwent PET imaging with (11)C-verapamil before and during infusion (6, 12, or 24 mg/kg

110 ials, although all data were consistent with verapamil binding in the pore.

111 domain III may contribute to a high affinity verapamil binding site accessed during 1-Hz stimulation

112 In contrast, the phenylalkylamine Br-verapamil binds in the central cavity of the pore on the

113 ll significantly reduced frequency-dependent verapamil block (1-Hz stimulation) in both Ba(2+) and Ca

114 n mutations abolished Ca(2+) potentiation of verapamil block at 0.05 Hz.

115 Verapamil block of Ca(v)1.2 is frequency-dependent and p

116 le sites may be required for potentiation of verapamil block of closed channels.

117 ), but little is known about state-dependent verapamil block of T channels.

118 Verapamil blocked currents at micromolar concentrations

119 At clinically relevant concentrations, verapamil blocked hCav1.2 and hERG, as did vanoxerine an

120 Verapamil blocked this response, indicating an extracell

121 In T-type calcium channels, verapamil blocks with micromolar affinity and has modest

122 al MDR susbtrates such as calcein-AM, bodipy-verapamil, bodipy-vinblastine, and mitoxantrone.

123 smethoxyverapamil (D888), is comparable with verapamil both in affinity and in state-dependence.

124 apamil radioactivity extraction ratio ((11)C-verapamil brain distributional clearance, K1/rCBF).

125 Dynamic (11)C-verapamil brain or fetal liver (reporter of placental P-

126 uivalent levels matched to those of standard verapamil, but lower than those of extended release vera

127 on of P-glycoprotein substrates morphine and verapamil, but not the tight junction marker, sucrose; t

128 anic cations carnitine, diphenhydramine, and verapamil, but penicillin and other organic anions faile

129 We determined that a dose adjustment of verapamil by 1.5-fold is required to compensate for conc

130 l control conferred by this newly identified verapamil-calcineurin-NFY signaling cascade was not limi

131 CQR including reduced drug accumulation and verapamil chemosensitization.

132 ethanol/water as solvent for the analysis of verapamil, citalopram, amitriptyline, lidocaine, and sun

133 Dynamic (11)C-verapamil data were assessed by a 2-tissue-compartment (

134 Verapamil decreased spatial dispersion of refractoriness

135 ha2-agonists, apical uptake was inhibited by verapamil, desipramine, and quinidine, but not by MPP+ (

136 ClC-2 inhibitor Cd2+, and the MDR-1 blocker verapamil did not affect EAA release or VRAC currents.

137 Verapamil did not affect nsPEF-induced Ca2+ transients,

138 The P-glycoprotein blocker verapamil did not interfere with (18)F-FBnTP cellular up

139 for resistance to GA overexpressed P-gp, but verapamil did not reverse the resistance.

140 d L-type Ca(2+) channels (LTCCs: nifedipine, verapamil, diltiazem) prevented the decrease in Ca(2+) t

141 embrane L-type Ca2+ channel blockers such as verapamil, diltiazem, and nifedipine, or the nonselectiv

142 out concurrent use of atorvastatin; digoxin; verapamil; diltiazem; amiodarone; fluconazole; ketoconaz

143 ignificantly different for concurrent use of verapamil; diltiazem; cyclosporine; ketoconazole, itraco

144 activity at the human BBB using PET of (11)C-verapamil distribution into the brain in the absence and

145 We found a significant increase in (R)-(11)C-verapamil distribution to the retina during ABCB1 inhibi

146 We found a significant increase in (R)-(11)C-verapamil distribution to the retina during ABCB1 inhibi

147 Treatment of cells with verapamil does not affect ES-induced [Ca2+]i increases,

148 ter levels were achieved for propafenone and verapamil drugs.

149 t rest: atenolol, metoprolol, diltiazem, and verapamil (drugs listed alphabetically by class).

150 erted into the outer leaflet of the bilayer, verapamil dynamically flip flops between the bilayer lea

151 e (+E, 3.3x10(-8); -E, 1.9x10(-8) mol/L) and verapamil (+E, 8.3x10(-8); -E, 7.8x10(-8) mol/L), and th

152 e, blocking the efflux function of P-gp with verapamil enhanced the therapeutic efficiency of (D)CDX-

153 le, ritonavir, clarithromycin, azithromycin, verapamil ER [extended release]), and diltiazem ER) on t

154 broadly prescribed calcium channel blockers (verapamil ER and diltiazem ER) and that the dose of colc

155 placers, including the single enantiomers of verapamil, fenoterol, and isoproterenol.

156 dazole (FMISO) for tissue hypoxia, and (11)C-verapamil for P-glycoprotein activity, in comparison wit

157 Colo-26 cells in the absence or presence of verapamil, for their dark and phototoxicity toward Colo-

158 acid and an intriguing conversion to liquid verapamil free base were observed upon disproportionatio

159 blocked significantly more slowly by charged verapamil from the outside, with an increase in apparent

160 as more common with participants in the COER-verapamil group (n = 118) compared with the atenolol or

161 ockers nicardipine, SKF96365, diltiazem, and verapamil had no effect at appropriate doses.

162 ydropyridine blockers, such as diltiazem and verapamil, had no effect on the CaSR-mediated rise in [C

163 transport is inhibited by the Pgp modulators verapamil (IC(50)=12.1 muM) and nifedipine, and also by

164 odels for calcium chloride (EC50 1.8 mM) and verapamil (IC50 0.61 muM); isoproterenol elicited a posi

165 apply compartmental modeling to these human verapamil imaging studies.

166 We found the ABC transporter inhibitor verapamil improved transduction efficiency 2- to 6-fold

167 d clinical trials, all of which investigated verapamil in acute mania, and finding no evidence that i

168 re monitored during infusion of SEA-0400 and verapamil in anesthetized dogs.

169 100 nM for reserpine or better than 5 nM for verapamil in aqueous solution.

170 tion of closed channels blocked by 30 microM verapamil in Ba(2+) but did not affect frequency-depende

171 cridar and distribution volumes of (R)-(11)C-verapamil in different brain regions.

172 lly, APAP increased P-gp transport of BODIPY-verapamil in freshly isolated rat brain capillaries.

173 patients with hypertrophic cardiomyopathy to verapamil in managing left ventricular outflow tract obs

174 Addition of P-gp substrate verapamil increased CSF 125I-T4 recovery to 51.4+/-2.8%,

175 oreover, application of the P-gp antagonist, verapamil, increased Dox loading in HSF-1(-/-) cardiomyo

176 coadministration of low-dose Cilengitide and Verapamil increases tumor angiogenesis, leakiness, blood

177 during apoptosis, which was also blocked by verapamil, indicating an important role for calcium in t

178 fCRT also transports quinine, quinidine, and verapamil, indicating that the protein behaves as a mult

179 we found that a CCAAT element was mediating verapamil-induced transcriptional repression and identif

180 Thus, verapamil induces a calcineurin-NFY signaling pathway th

181 terally symmetric in chronically stimulated, verapamil-infused animals.

182 S(4)) were determined at baseline and during verapamil infusion.

183 Our finding that verapamil inhibits intracellular M. tuberculosis growth

184 ces among MATE transporters, and suggest how verapamil inhibits MATE-mediated multidrug efflux.

185 ndomethacin, 2-aminoethoxydiphenylborane, or verapamil inhibits repair of the damage and also inhibit

186 n occurs by a competitive mechanism, whereas verapamil inhibits transport by a non-competitive mechan

187 11)C were integrated over 0-9 min after each verapamil injection.

188 -gp increased blood-brain transfer (K(1)) of verapamil into the brain by 73% (range, 30%-118%; n = 12

189 Verapamil is a potent phenylalkylamine antihypertensive

190 Verapamil is a prototypical phenylalkylamine (PAA), and

191 As verapamil is a substrate for CYP3A4, which is induced by

192 Verapamil is the only inhibitor that reduced the express

193 In addition to 'verapamil-like' chemosensitization to chloroquine and am

194 Verapamil markedly accelerated the rate of tight binding

195 contrast, the L-type calcium channel blocker verapamil markedly decreased S1P-induced HASM cell contr

196 harmacological therapy with beta-blockade or verapamil may realize meaningful symptom relief and low

197 Our data further suggest that this verapamil-mediated TXNIP repression is conferred by redu

198 le higher than therapeutic concentrations of verapamil (micromolar) were necessary to inhibit activit

199 PET scans with the ABCB1 substrate (R)-(11)C-verapamil on 5 healthy male volunteers without and with

200 PET scans with the ABCB1 substrate (R)-(11)C-verapamil on 5 healthy male volunteers without and with

201 more, reducing the wild-type VSMC [Ca2+]i by Verapamil or BAPTA-AM significantly increased cellular c

202 reducing calcium conductance (gCa(V)) using verapamil or by reducing gap junctional conductance (Gj)

203 ions of the first generation P-gp inhibitors verapamil or cyclosporin, respectively.

204 patients with a discharge diagnosis of acute verapamil or diltiazem overdose at five university-affil

205 try that was inhibited with SKF96365 but not verapamil or KB-R7943.

206 Intra-BLA infusions of verapamil or nifedipine did not affect the expression of

207 h the P-glycoprotein inhibitors quinidine or verapamil) or warfarin (dose adjusted to maintain the in

208 odipine or isradipine, but not by diltiazem, verapamil, or cadmium.

209 etreatment with topical cyclosporin A (CsA), verapamil, or XR9576, modulators of P-glycoprotein (P-gp

210 or tariquidar followed by another (R)-[(11)C]verapamil PET scan 60 min later.

211 and November, 2011, we completed (R)-[(11)C]verapamil PET studies in 14 pharmacoresistant patients,

212 ) to inhibit P-gp, a second set of water and verapamil PET studies was conducted, followed by (11)C-C

213 Molecular imaging with verapamil-PET identifies P-glycprotein overexpression as

214 Voxel-by-voxel, we calculated the (R)-[(11)C]verapamil plasma-to-brain transport rate constant, K1 (m

215 Gd(3+) and verapamil potentiated the HK-induced increase in [Ca(2+)

216 showed that inhibition of TXNIP by siRNA or verapamil prevented Hcys-induced TXNIP protein recruitme

217 Importantly, pretreatment with verapamil prevented scopolamine-induced behavioral respo

218 In addition, we found that verapamil prevented the release of [(3)H]arachidonic aci

219 ype, whereas the calcium channel antagonist, verapamil, prevented abnormal outcome in Kir6.2-KO.

220 oprotein activity was expressed as the (11)C-verapamil radioactivity extraction ratio ((11)C-verapami

221 of P-gp function, the distribution of (11)C-verapamil radioactivity into these compartments is limit

222 Efflux pump inhibitors like verapamil reduce this tolerance.

223 The L-type Ca2+ channel blocker verapamil reduced SS Ca2+ spark frequency to 38% of cont

224 Moreover, verapamil reduced tolerance to bedaquiline and moxifloxa

225 nd human islets and that orally administered verapamil reduced TXNIP expression and beta-cell apoptos

226 nhibition of mycobacterial efflux pumps with verapamil reduces the bacterial drug tolerance and may e

227 tibody (UIC2) and a fluorescent drug (Bodipy-verapamil), respectively.

228 of 821.9 and 2.2 mg/kg for carbamazepine and verapamil, respectively.

229 SL-ATP to wild-type P-gp in the presence of verapamil resulted in reduction of the protein-bound spi

230 An L-type Ca(2+) channel blocker, verapamil, reversed some beneficial effects of GRK2KO.

231 preceding residue 76 modulate the degree of verapamil reversibility in CQ-resistant lines.

232 yrin IX in the digestive vacuole and loss of verapamil reversibility of CQ and quinine resistance.

233 have now proven that pfcrt mutations confer verapamil-reversible chloroquine resistance in vitro and

234 resistance transporter (PfCRT) can result in verapamil-reversible CQ resistance and altered susceptib

235 Verapamil's R isomer and its metabolite norverapamil hav

236 ogenase-positive cells as well as cells with verapamil-sensitive ability to efflux rhodamine 123.

237 cilia-specific effect independent of V2R or verapamil-sensitive calcium channels.

238 east cancer-resistance protein 1-expressing, verapamil-sensitive SP of candidate cancer stem cells.

239 reast cancer-resistance protein 1-expressing verapamil-sensitive SPs in three of four human ovarian c

240 onal inhibition of ABCB1 using vardenafil or verapamil significantly (p <= 0.05-0.001) potentiated th

241 or 0.70, respectively) and trandolapril with verapamil SR (HRs 0.78 and 0.79) were associated with re

242 follow-up BP and addition of trandolapril to verapamil SR each were associated with reduced risk.

243 lease)/trandolapril in INVEST (INternational VErapamil SR Trandolapril STudy) were categorized into 3

244 the 22,576 participants in the International Verapamil SR-Trandolapril Study (INVEST).

245 ients and 1000 patients of the International Verapamil SR/Trandolapril Study (INVEST) Genetic Substud

246 is of either atenolol/hydrochlorothiazide or verapamil-SR (sustained release)/trandolapril in INVEST

247 ctivity of ABCG2, whereas both the basal and verapamil-stimulated ATPase activities of P-gp were inhi

248 -linking of mutant A259C/W803C inhibited its verapamil-stimulated ATPase activity mutant, but activit

249 Q2 was also an inhibitor of verapamil-stimulated ATPase activity.

250 n with the L-type antagonists nifedipine and verapamil strongly diminished the phloretin-sensitive ap

251 The presence of verapamil strongly magnified both effects.

252 activity and mitofusin 1 (Mfn1), because (i) verapamil suppressed both contraction and mitochondrial

253 In vivo, amlodipine and verapamil suppressed peritoneal macrophage recruitment i

254 CAD that were assigned randomly to either a verapamil sustained-release (SR)- or an atenolol-based s

255 ents from INVEST were randomly assigned to a verapamil sustained-release- or atenolol-based strategy;

256 Sav1866 displayed a Hoechst 33342, verapamil, tetraphenylphosphonium, and vinblastine-stimu

257 side population cells and can be blocked by verapamil, they do not express increased levels of the A

258 radiolabeled P-glycoprotein substrates, (3)H-verapamil (threefold increase), (3)H-loperamide (fivefol

259 ater to assess blood flow, followed by (11)C-verapamil to assess BBB P-gp activity.

260 We also found verapamil to be a partial mixed-type inhibitor of chloro

261 Group 4 received verapamil to evaluate the effect of calcium channel bloc

262 ations with the use of either terfenadine or verapamil to inhibit INa and ICa or pinacidil to activat

263 current agonist pinacidil or I(Ca,L) blocker verapamil to maintain AP duration (APD) near control lev

264 clinically approved calcium channel blocker verapamil to obese mice.

265 4.7 (1.4-15.9) times less likely to require verapamil to treat cardiovascular instability than those

266 wed potent inhibition (comparable to that of verapamil) toward the whole-cell drug efflux pump activi

267 The INternational VErapamil-trandolapril STudy (INVEST) compared outcomes

268 dary analysis of data from the International Verapamil-Trandolapril Study (INVEST), which was conduct

269 The verapamil-trandolapril-based strategy was as clinically

270 inhibition by CsA, indicated by a change in verapamil transport (K(1)).

271 o gain detailed insight into the kinetics of verapamil transport across the blood-brain barrier (BBB)

272 ntly inhibited boron-dipyrromethene (BODIPY)-verapamil transport mediated by human P-gp (IC(50) 2.4 +

273 gle-Q-loop mutants are functional for Bodipy-verapamil transport.

274 Inhibition of P-gp unmasks verapamil trapping in brain tissue that requires a 2C mo

275 Diltiazem and verapamil traverse the central cavity of the pore domain

276 pinacidil-treated myocytes, but depressed in verapamil-treated myocytes.

277 Echocardiography of verapamil-treated, gamma-sarcoglycan-null mice showed an

278 Verapamil treatment eliminated evidence of vasospasm and

279 However, verapamil treatment significantly attenuated both cardia

280 nsitized cardiac dysfunction upon short-term verapamil treatment.

281 ated by DLMC+US than those treated by DL, DL+verapamil under the same US treatment or DLMC without US

282 cases of cells treated by DLMC, DL+US or DL+verapamil+US.

283 ) were also mutated and assayed for block by verapamil using whole-cell voltage-clamp recordings in 1

284 of three drugs (promethazine, enalapril, and verapamil) using deuterated analogues of these drugs as

285 olarizations (EADs) and arrhythmias, whereas verapamil, vanoxerine and bepridil produced no proarrhyt

286 urnover ( k cat <or= 1-2 s (-1)) compared to verapamil (VER) ( k cat approximately 10 s (-1)).

287 strate that many other substrates (including verapamil, vinblastine, and rifampicin) of the well stud

288 ransporter (PfCRT) are major determinants of verapamil (VP)-reversible CQ resistance (CQR).

289 cally relevant doses of chloroquine (CQ) and verapamil (VPL) and thereby present the first in vivo qu

290 also inspect how pH, the chemoreversal agent verapamil (VPL), and various amino acid mutations in PfC

291 0 times more effective reversal ability than verapamil (VRP) for TAX and VCR.

292 maceutical drugs, such as Norepinephrine and Verapamil was achieved with excellent sensitivity.

293 Permanently charged verapamil was more effective intracellularly than neutra

294 il, but lower than those of extended release verapamil, we evaluated the activity of verapamil added

295 holamine infusion, and response to adenosine/verapamil were evaluated.

296 at 375 K show how the drugs daunorubicin and verapamil, which were initially docked into the ABC tran

297 al) distribution of lipophilic drugs such as verapamil will be limited by tissue blood flow.

298 e for 500 nM to 1.0 mM solutions (n = 11) of verapamil with R(2) = 0.988.

299 of analytes (e.g., approximately 800 zmol of verapamil) with a dynamic range spanning up to 4 orders

300 A lower dose of verapamil without effects on left ventricular pressure (